Welcome to our dedicated page for SOPHiA GENETICS SA SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA (SOPH) has a notice under Rule 144 indicating that officer Zhenyu Xu plans to sell up to 6,000 shares of common stock through Morgan Stanley Smith Barney LLC on or after August 20, 2026. The shares are identified as founders shares originally acquired from the issuer on June 20, 2012.
The notice also lists recent 10b5-1 sales of SOPHiA GENETICS common stock by Zhenyu Xu over the past three months, including individual transactions ranging from 3,000 to 17,000 shares with specified aggregate dollar amounts for each sale.
SOPHiA GENETICS SA (SOPH) has a notice of proposed sale of securities filed under Rule 144 by officer Manuela Valente. The filing covers the planned sale of 10,000 shares of common stock, to be issued via exercise of stock options for cash and sold through Morgan Stanley Smith Barney LLC on NASDAQ on 08/19/2026. The notice also lists a prior Rule 10b5-1 sale of 4,241 shares of common stock on 07/06/2026.
SOPHiA GENETICS SA (SOPH) received a notice that officer Zhenyu Xu intends to sell 8,000 shares of common stock under Rule 144. The shares are held at Morgan Stanley Smith Barney LLC Executive Financial Services and relate to founder shares originally acquired on 06/20/2012.
The notice also lists prior sales of SOPH common stock by Zhenyu Xu during the past three months under a Rule 10b5-1 trading plan, with individual sale dates, share amounts, and total proceeds disclosed.
Philippe Menu, Chief Medical Officer of SOPHiA GENETICS SA, sold 5,000 Ordinary Shares of the company on 2026-08-12 in an open-market transaction under a duly adopted Rule 10b5-1(c) trading plan. The weighted average sale price was $7.5159 per share, with individual trades executed between $7.40 and $7.60 per share. Following this sale, Menu directly holds 218,387 Ordinary Shares.
SOPHiA GENETICS SA Chief Scientific Officer Zhenyu Xu reported a sale of 4,000 Ordinary Shares on August 13, 2026. The shares were sold at a weighted average price of $7.5191 per share, in multiple trades between $7.43 and $7.62. After this transaction, Xu directly holds 586,887 Ordinary Shares. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.
SOPHiA GENETICS SA Chief Technology Officer Abhimanyu Verma reported a sale of 5,000 Ordinary Shares of SOPH on 2026-08-07 at $7.60 per share in an open market or private transaction. After this transaction, he directly holds 182,171 Ordinary Shares. The sale was made pursuant to a duly adopted Rule 10b5-1(c) trading plan.
SOPHiA GENETICS SA Executive Chairman Jurgi Camblong reported two non-derivative stock sales of Ordinary Shares pursuant to a duly adopted Rule 10b5-1(c) trading plan. On August 7, 2026, he sold 20,000 shares at a weighted average price of $7.227, in multiple trades between $7.20 and $7.27. On August 10, 2026, he sold 8,500 shares at a weighted average price of $7.6081, in multiple trades between $7.50 and $7.80. Post-transaction share holdings are not specified in this filing.
SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu reported option exercises and share sales in early August 2026. He exercised options for 10,000 Ordinary Shares at $3.2800 per share and sold 20,000 Ordinary Shares at prices between $7.00 and $7.56 under a Rule 10b5-1(c) trading plan, while retaining 975,041 derivative share options.
SOPH reports a planned sale of 22,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $147,180.00. The planned sale includes 2,000 shares from an 08/07/2026 Exercise of Stock Options and 20,000 Founders Shares originally dated 06/20/2012. Recent activity shows multiple Rule 10b5-1 sales by Zhenyu Xu between May and August 2026.
SOPHiA GENETICS SA is registering a proposed sale of 20,000 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $133,800.00 as of the filing, and an anticipated sale date of August 7, 2026.
The filing also lists prior Rule 10b5-1 plan sales of common shares by Jurgi Camblong over the past three months, including transactions such as 65,269 shares sold on June 30, 2026 for $398,632.27 and 50,069 shares sold on June 26, 2026 for $290,329.01.